Alerta

ADJUSTING INSULIN DELIVERY RATES

Resumen de: US2025262381A1

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.

Methods For Reduction of Battery Usage In Ambulatory Infusion Pumps

Resumen de: US2025267580A1

A battery-powered infusion pump for medicament delivery (e.g., insulin) may collect and store data related to the pump. The infusion pump can communicate some or all of the stored data to another device and control the timing and amount of data communicated in order to conserve battery life.

FLEXIBLE ELECTRONICS FOR ANALYTE DETECTION

Resumen de: US2025261881A1

A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.

COMPOSITIONS FOR GLUCOSE-RESPONSIVE DRUG DELIVERY SYSTEMS VIA MULTIFUNCTIONAL HYDROGEL-BASED MICRONEEDLE

Resumen de: WO2024077402A1

The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa ~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.

ELECTRONIC APPARATUS AND CONTROLLING METHOD THEREOF

Resumen de: EP4604136A1

A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.

RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE

Resumen de: EP4603003A2

Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a "retrofitting" algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algor

Apparatus, methods and computer programs for detecting critical events

Resumen de: GB2638147A

A system 100 comprises a number of devices 102 in communication with one another. The devices 102 are associated with a user 104 and may comprise a smartphone 102A, wearable devices such as a headset 102B or heart rate monitor 102C, and other local devices 102D,102E such as smart speakers including a microphone, cameras, motion sensors or other devices used for monitoring the area around the user 104. The wearable devices may comprise sensors for monitoring physiological parameters or an IMU for monitoring position or movement of the user 104. One or more of the devices 102 can be configured to detect a critical event. A critical event is an event considered to be dangerous or causes the user to require assistance such as cardiac events, a drop in blood sugar level, or a fall. If a critical event occurs, one or more of the devices 102 can raise an alarm or contact assistance. Before such takes place, the system confirms that a prospective critical event is an actual critical event by obtaining additional data from another device 102 in the system. This can help to avoid false alarms or other calls for assistance being raised unnecessarily.

BLOCKAGE DETECTION DEVICE FOR DIABETIC INSULIN INJECTION PUMP

Resumen de: LU600247B1

The invention belongs to the technical field of pressure monitoring, in particular to a blockage detection device for a diabetic insulin injection pump, which comprises a gun shell, wherein an injection refill is arranged in the barrel of the gun shell, a refill piston is arranged in the injection refill, an injection pipeline is arranged at one end of the injection refill near the muzzle of the gun shell, the injection pipeline extends out of the gun shell; one side of the refill piston near the injection pipeline is provided with a membrane pressure sensor, a driving mechanism for driving the refill piston to move is arranged inside the gun body of the gun shell; a handle of the gun shell is provided with a manual switch assembly, a controller, a blood sugar monitoring module and an alarm prompt system.

INTRAVASCULAR ARTIFICIAL PANCREAS

Resumen de: AU2024219128A1

Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.

METHOD FOR MANAGING MEDICAL DATA

Resumen de: US2025259720A1

This disclosure relates to a method, a mobile device, and a computer program, for managing medical data such as, e.g., glucose concentrations, by an electronic disease management system. In the method a change of the local time between generation of a first set of medical data and a second set of medical data is detected.

SYSTEM AND METHOD FOR ADJUSTING INSULIN DELIVERY

Resumen de: US2025256027A1

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and/or determining one or more user specific dosage parameters.

ELECTRONIC APPARATUS AND CONTROLLING METHOD THEREOF

Resumen de: US2025255561A1

A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.

MACHINE-LEARNING-BASED MEAL DETECTION AND SIZE ESTIMATION USING CONTINUOUS GLUCOSE MONITORING (CGM) AND INSULIN DATA

Resumen de: US2025259727A1

Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.

INFUSION DEVICES AND RELATED RESCUE DETECTION METHODS

Resumen de: EP4599864A2

Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device (100, 500) to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.

PUMP ENGINE WITH METERING SYSTEM FOR DISPENSING LIQUID MEDICATION

Resumen de: EP4599866A2

An infusion pump system is disclosed for dispensing liquid medication, such as insulin. The infusion pump system includes a first reservoir for storing liquid medication, a first fluid driver for exerting pressure on the first reservoir, a second reservoir for storing liquid medication, and a second fluid driver for exerting pressure on the second reservoir. One or more valves are used to permit flow of liquid medication from the first reservoir to the second reservoir, and to permit flow of liquid medication from the second reservoir to an infusion site. Each of the valves is selectively opened or closed to fill the second reservoir with liquid medication from the first reservoir and to dispense liquid medication from the second reservoir to the infusion site. A controller and one or more sensors are used to monitor and control the system.

SYSTEM AND DEVICE OF DYNAMIC GLUCOSE PROFILE RESPONSE TO PHYSIOLOGICAL PARAMETERS

Resumen de: EP4601278A2

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.

CONTINUOUS ANALYTE MONITOR DATA RECORDING DEVICE OPERABLE IN A BLINDED MODE

Resumen de: EP4601218A2

A system is provided for monitoring analyte in a host, including a continuous analyte sensor that produces a data stream indicative of a host's analyte concentration and a device that receives and records data from the data stream from the continuous analyte sensor. In one embodiment, the device includes a single point analyte monitor, from which it obtains an analyte value, and is configured to display only single point analyte measurement values, and not any analyte measurement values associated with data received from the continuous analyte sensor. Instead, data received from the continuous analyte sensor is used to provide alarms to the user when the analyte concentration and/or the rate of change of analyte concentration, as measured by the continuous analyte sensor, is above or below a predetermined range. Data received from the continuous analyte sensor may also be used to prompt the diabetic or caregiver to take certain actions, such as to perform another single point blood glucose measurement. In another embodiment, the device provides for toggling between two modes, with one mode that allows for display of glucose concentration values associated with the continuous glucose sensor and a second mode that prevents the display of glucose concentration values associated with the continuous glucose sensor.

MINIMALLY INVASIVE GLUCOSE STATE SYSTEMS, DEVICES, AND METHODS

Resumen de: WO2024077303A2

Glucose systems that include a minimally invasive scalp-worn device that includes first and second sensors. The systems are adapted to determine one or more glucose states based on sensed EEG signals using the scalp-worn device.

Methods and systems for insulin delivery and glucose measurement

Resumen de: US12383675B1

In an aspect, the present disclosure provides a method comprising: (a) positioning an insulin delivery device on a body of a subject via a single puncture site in said body of said subject; (b) using said insulin delivery device to deliver an insulin or insulin analog formulation to said subject via said single puncture site; and (c) using a sensor of said insulin delivery device to measure a glucose concentration in said body of said subject via said single puncture site, wherein (b) and (c) are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning in (a), while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

Non-Invasive Blood Glucose Prediction by Deduction Learning System

Resumen de: US2025248624A1

The present invention relates to a system and method for predicting blood glucose levels in a non-invasive manner using deduction learning. The deduction learning (DL) model 10 of the present invention predicts blood glucose level 300 based on the relationship or correlation between blood glucose level variation and PPG signal variation. Specifically, the DL model 10 of the present invention comprises a differential cell 100 (DC) configured to calculate predicted blood glucose level BGpred 300 using two PPG signals Si 200b and Si−1 200a, a BG i−1,ref 230 and relationship or correlation between variances of the two PPG signals and variances of the reference blood glucose level 230 and the predicted blood glucose level 300.

OVERTAPE DESIGNS FOR DEVICES SUCH AS GLUCOSE SENSORS

Resumen de: US2025248654A1

Embodiments of the invention provide skin adhesive patches designed to ease a diabetic patient's maneuverability and alignment of a glucose sensing device as the patient adheres the device to their skin. Embodiments of the invention can be adapted for use with a wide variety of medical components that are coupled to the skin of patients, including insulin infusion sets, patch pumps, and all-in-one patch sets.

INSULIN MANAGEMENT

Resumen de: US2025253045A1

A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment for tube-fed patients from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

DIABETES MANAGEMENT SYSTEM

Resumen de: US2025249171A1

A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to PWD designated assistance entities (e.g., family, friends, givers, HCPs, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the PWD will immediately perform the designated maintenance task. In some cases, methods, devices, and systems provided herein can use proximity to non-paired mobile computing devices to deliver data to PWD designated assistance entities.

METHOD AND SYSTEM FOR CALCULATING INSULIN DOSING PARAMETERS IN COMPUTER AIDED DOSING

Resumen de: WO2025166261A1

A computer implemented method for controlling insulin dosing for a subject includes saving field collected glucose and insulin data for the subject. The method implements a virtual personal model, or digital twin, of the subject by using the field collected data to save electronic field collected traces of blood glucose levels and electronic field collected traces of insulin levels for the subject. A replay phase of the virtual personal model emulates test insulin therapies to generate virtual insulin doses that correspond to the field collected data. The method converges to a result by comparing field collected glucose traces and regenerated glucose traces. This method recommends a basal rate profile for the subject using saved replay data by calculating inversions of the virtual personal model by deconvolution.

ACCESSORY DEVICE, AND SYSTEM COMPRISING SAME FOR MANAGING BLOOD GLUCOSE

Nº publicación: WO2025164955A1 07/08/2025

Solicitante:

BENCH SOFT CO LTD [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uBCA4\uCE58\uC18C\uD504\uD2B8

Resumen de: WO2025164955A1

Provided is a system for managing blood glucose, the system comprising: a bio-apparatus for measuring biosignals including blood glucose; and a drug injection device for injecting drug for controlling blood glucose in the body, wherein the bio-apparatus and drug injection device are each provided with at least one electrode for connecting to the human body, and transmit and receive electrical signals between each other with the human body as the medium, and the bio-apparatus is provided with a power reception circuit for receiving operational power from the drug injection device.